News & Events:VXRT

A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that Vaxart’s S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2.

Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Vaxart, Inc. (VXRT) breached their fiduciary duties of loyalty, good faith and candor and whether the Company suffered substantial harm as a result.

Vaxart Inc (VXRT): * Vaxart Inc (VXRT)- ON MAY 10 CO RETAINED FUAD AHMAD AS CO'S INTERIM CFO WHILE VAXART CONDUCTS ITS ONGOING SEARCH FOR A CHIEF FINANCIAL OFFICER Source text for Eikon: [https://bit.ly/3Pccrqn] Further company coverage:

  On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

Vaxart Inc (VXRT): * VAXART PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $0.20 Source text for Eikon: Further company coverage:

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1st Quarter with $157.0 million in cash, cash equivalents and marketable securities Vaxart (VXRT), Inc. issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.

  During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  Wednesday's session saw 784 companies set new 52-week lows. The following stocks set new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  During Tuesday, 581 stocks hit new 52-week lows. Meta Platforms was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science. During Tuesday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  On Friday, 431 companies hit new 52-week lows. Here are all the stocks that set new 52-week lows on Friday: Be sure to stay with Benzinga for further updates and market-moving news.

Vaxart, Inc. (VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.  The title of Dr. Tucker’s presentation is “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.

FinancialBuzz.com News Commentary NEW YORK, April 5, 2022 Recent data regarding the pandemic has revealed that hospitalizations and death rates are rising once again. As a result of the pandemic's unceasing nature, COVID-19 testing kits are in short supply.

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 -- Vaxart (VXRT), Inc. issued its business updat...

Vaxart Inc (VXRT): * Vaxart Inc (VXRT) - VAXART'S S-ONLY COVID-19 VACCINE CANDIDATE PRODUCES STRONG-CROSS REACTIVE MUCOSAL AND SYSTEMIC IMMUNE RESPONSES IN NON-HUMAN PRIMATES. * Vaxart Inc (VXRT) - VAXART'S S-ONLY CANDIDATE INDUCED A 1000-FOLD INCREASE IN NASAL IGA RESPONSES TO VARIANTS, * Vaxart Inc (VXRT) - DATA IS EXPECTED IN FIRST HALF OF 2022.

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on re...

Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team Vaxart (VXRT), Inc. today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences.

Vaxart, Inc. (VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, including Omicron SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 -- Vaxart (VXRT), Inc. said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine ...